This data comes from pipes.yahoo.com but the Pipe does not exist or has been deleted.
Author: OphthalmologyWeb
Visual Benefits Of Anti-VEGF Therapy May Diminish Upon Extended Dosing
Long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration suggest that eyes with good visual acuities require long-term regular dosing, according to a presentation here.
Visual Benefits Of Anti-VEGF Therapy May Diminish Upon Extended Dosing
Long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration suggest that eyes with good visual acuities require long-term regular dosing, according to a presentation here.
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
KalVista Pharmaceuticals Launched With 8 Million In Series A Funding To Develop Novel Class Of Drugs For Diabetic Macular Edema
KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.
Kellogg Researcher Helping Eye Care Providers Better Assess Driving In Older Adults
Drivers over age 65 are the fastest-growing segment of the driving population, and their eye care providers-ophthalmologists and optometrists-are playing an increasingly important role in assessing their ability to drive safely.
MIVI-TRUST Outcomes Strengthen Support Of Ocriplasmin For Vitreomacular Adhesion
Ocriplasmin may become the first pharmacologic option for patients with vitreomacular adhesion, according to two presentations here.
Abbott Receives CE Mark For Healon EndoCoat Protective Gel For Cataract Surgery
Abbott announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD.
Sosei To Receive Grant From NEDO’s FY2011 Innovation Promotion Programme For Development Of Innovative Ophthalmic Solutions
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. (“Activus”) is to receive a grant for its “Development of Innovative Ophthalmic Solutions” from the New Energy and Industrial Technology Development Organizati…
Volk Pictor Portable Imager At Vision West
Mentor, Ohio (August 19, 2011) – Volk Optical’s new Pictor digital imaging device will demonstrate its ease of use outside the office at Vision West September 22 – 24, 2011 at the Sands Expo and Convention Center (Las Vegas, Nev.). At Volk’s exhibit in…
ThromboGenics Announces New Phase III Ocriplasmin Data Presented At The 2011 Annual Meeting Of The American Society Of Retina Specialists (ASRS)
New data presented by leading retinal specialists Dr Pravin U. Dugel, MD (Phoenix, AZ) and Dr Peter K. Kaiser, MD (Cleveland, OH)
Short-Term Dark Adaptation May Be More Reliable In Identifying Primary Angle-Closure Suspects
Assessment of the anterior chamber angle configuration may be more reliable if performed after a short-term dark adaptation of 3 minutes, a study found.
Vision Problems Common After Glaucoma Surgery
More than half of people getting a certain type of glaucoma surgery may suffer from temporary, sometimes severe vision loss afterwards, suggests a new study. A smaller proportion — about 8 in every 100 — could have some degree of permanent vision los…
Short-Term Dark Adaptation May Be More Reliable In Identifying Primary Angle-Closure Suspects
Assessment of the anterior chamber angle configuration may be more reliable if performed after a short-term dark adaptation of 3 minutes, a study found.
Webinar: LENSTAR LS 900® The First Optical Biometer of the Entire Eye
In this international webinar “Best Practices for IOL Power Measurements – Advanced Optical Biometry: Better Outcomes” Warren E. Hill, MD (East Valley Ophthalmology, Mesa, Arizona), explains that the ever increasing patient expectations, which along wi…
Vision Problems Common After Glaucoma Surgery
More than half of people getting a certain type of glaucoma surgery may suffer from temporary, sometimes severe vision loss afterwards, suggests a new study. A smaller proportion — about 8 in every 100 — could have some degree of permanent vision los…
LasikPlus® Invites You To Grand Re-Opening Event On August 19th At Rockville Center
LasikPlus®, a leading provider of laser vision correction, is hosting a Grand Re-Opening Event in its recently relocated Rockville Vision Center on Friday, August 19th from 11 a.m. to 2 p.m.
LasikPlus® Invites You To Grand Re-Opening Event On August 19th At Rockville Center
LasikPlus®, a leading provider of laser vision correction, is hosting a Grand Re-Opening Event in its recently relocated Rockville Vision Center on Friday, August 19th from 11 a.m. to 2 p.m.
Eye Consultants Of Texas First In Dallas/Ft. Worth To Offer New Cataract Surgery Technology
Eye Consultants of Texas is the first ophthalmology practice in Dallas/Fort Worth to use the ORange®, the world’s first Intraoperative Wavefront Aberrometer that provides real-time measurements of the patient’s eye during cataract surgery. Prior to OR…